Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting.

Pellicano F, Mukherjee L, Holyoake TL.

Stem Cells. 2014 Jun;32(6):1373-9. doi: 10.1002/stem.1678. Review.

3.

Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Sato T, Goyama S, Kataoka K, Nasu R, Tsuruta-Kishino T, Kagoya Y, Nukina A, Kumagai K, Kubota N, Nakagawa M, Arai S, Yoshimi A, Honda H, Kadowaki T, Kurokawa M.

Oncogene. 2014 Oct 16;33(42):5028-38. doi: 10.1038/onc.2014.108. Epub 2014 Apr 21.

4.

Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.

Valent P, Deininger M.

Leuk Lymphoma. 2008 Apr;49(4):604-9. doi: 10.1080/10428190801923212. Review.

PMID:
18398718
5.

Characterization of cancer stem cells in chronic myeloid leukaemia.

Jørgensen HG, Holyoake TL.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1347-51. Review.

PMID:
17956348
6.

Hurdles toward a cure for CML: the CML stem cell.

Gallipoli P, Abraham SA, Holyoake TL.

Hematol Oncol Clin North Am. 2011 Oct;25(5):951-66, v. doi: 10.1016/j.hoc.2011.09.001. Epub 2011 Oct 19. Review.

PMID:
22054728
7.

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ.

J Clin Invest. 2011 Jan;121(1):396-409. doi: 10.1172/JCI35721. Epub 2010 Dec 13. Erratum in: J Clin Invest. 2011 Mar 1;121(3):1222.

8.

Stem-cell driven cancer: "hands-off" regulation of cancer development.

Vicente-Dueñas C, Pérez-Caro M, Abollo-Jiménez F, Cobaleda C, Sánchez-García I.

Cell Cycle. 2009 May 1;8(9):1314-8. Epub 2009 May 18.

PMID:
19279406
9.

BCR-ABL kinase is dead; long live the CML stem cell.

Perl A, Carroll M.

J Clin Invest. 2011 Jan;121(1):22-5. doi: 10.1172/JCI43605. Epub 2010 Dec 13.

10.

Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.

Xiao M, Ai H, Li T, Rajoria P, Shahu P, Li X.

Biochem Biophys Res Commun. 2016 Apr 15;472(4):610-6. doi: 10.1016/j.bbrc.2016.03.018. Epub 2016 Mar 8.

PMID:
26966074
11.

Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.

Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V.

Blood. 1996 Oct 15;88(8):3091-100.

12.

Impaired immunomodulatory function of chronic myeloid leukemia cancer stem cells and the possible mechanism involved in it.

Xishan Z, Xinna Z, Baoxin H, Jun R.

Cancer Immunol Immunother. 2013 Apr;62(4):689-703. doi: 10.1007/s00262-012-1367-5. Epub 2012 Nov 21.

PMID:
23180012
13.

Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.

Helgason GV, Karvela M, Holyoake TL.

Blood. 2011 Aug 25;118(8):2035-43. doi: 10.1182/blood-2011-01-330621. Epub 2011 Jun 21. Review.

14.

Targeting chronic myeloid leukemia stem cells.

Kinstrie R, Copland M.

Curr Hematol Malig Rep. 2013 Mar;8(1):14-21. doi: 10.1007/s11899-012-0148-8. Review.

PMID:
23264204
15.

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.

Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Müller-Tidow C, Bhatia R, Brunton VG, Koschmieder S, Holyoake TL.

Blood. 2012 Feb 9;119(6):1501-10. doi: 10.1182/blood-2010-12-326843. Epub 2011 Dec 19.

16.

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR.

Sci Transl Med. 2014 Sep 3;6(252):252ra121. doi: 10.1126/scitranslmed.3009073.

17.

Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform.

Faley S, Copland M, Reboud J, Cooper JM.

Integr Biol (Camb). 2012 Apr;4(4):368-73. doi: 10.1039/c2ib00086e. Epub 2012 Feb 20.

PMID:
22344285
18.

The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?

Carter BZ, Mak DH, Cortes J, Andreeff M.

Semin Hematol. 2010 Oct;47(4):362-70. doi: 10.1053/j.seminhematol.2010.06.006. Review.

19.

Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.

Ramos TL, Sánchez-Abarca LI, López-Ruano G, Muntión S, Preciado S, Hernández-Ruano M, Rosado B, de las Heras N, Chillón MC, Hernández-Hernández Á, González M, Sánchez-Guijo F, Del Cañizo C.

Leuk Res. 2015 Aug;39(8):921-4. doi: 10.1016/j.leukres.2015.05.014. Epub 2015 Jun 11.

PMID:
26105049
20.

Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.

Chen Y, Peng C, Sullivan C, Li D, Li S.

Leukemia. 2010 Sep;24(9):1545-54. doi: 10.1038/leu.2010.143. Epub 2010 Jun 24. Review.

Supplemental Content

Support Center